Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest®for continuous combined hormone replacement therapy in postmenopausal women

T Gräser, Rossen Koytchev, Antonia Müller, M. Öettel
In: Climacteric · 2000 · vol. 3(2) , pp. 109–118 · doi:10.3109/13697130009167612 · W2066469488
article OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study found estradiol valerate/dienogest combinations to be therapeutically equivalent to Kliogest for postmenopausal symptoms with similar endometrial safety but differing vaginal bleeding patterns and effects on certain biomarkers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Objective To compare the efficacy and endometrial safety of two estradiol valerate/dienogest combinations with Kliogest® in the treatment of postmenopausal symptoms.Design This was a double-blind, randomized, multicenter study.Methods Patients were randomized to estradiol valerate 2.0 mg/dienogest 2.0 mg (Climodien®), estradiol valerate 2.0 mg/dienogest 3.0 mg (E2Val 2/DNG 3); or estradiol 2.0 mg/estriol 1.0 mg/norethisterone acetate 1.0 mg (Kliogest®) once daily for 1 year. The primary efficacy variable was the Kupperman index. Endometrial safety was determined primarily by biopsy.Results and Conclusions Climodien and E2Val 2/DNG 3 were therapeutically equivalent to Kliogest (mean changes in Kupperman index -20.1, -19.0 and -18.3, respectively). No statistically significant differences existed between treatment groups in the severity of postmenopausal symptoms. The incidences of endometrial atrophy were similar in all groups. Climodien appeared to be superior to Kliogest in terms of vaginal bleeding pattern, whereas E2Val 2/DNG 3 was associated with a slightly higher incidence and greater intensity of vaginal bleeding. The incidences of adverse events were similar in all groups. A greater proportion of women in the Kliogest and E2Val 2/DNG 3 groups experienced vaginal bleeding, whereas breast problems were more common with Climodien. Climodien and E2Val 2/DNG 3 induced desirable changes in insulin-like growth factor I (decrease) and sex hormone binding globulin (increase) that were not seen with Kliogest.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (17)

Source provenance

openalex
last seen: 2026-05-10T10:53:45.871304+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK